Osama Mohamed, MD, PhD, University of California, San Francisco, CA discusses unmet needs in prostate cancer treatment. Improved patient selection and treatment personalisation is needed to optimise patient outcomes. The development of a predictive biomarker will enable identification of patients who will most benefit from a particular therapy. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.